Dr. Kirsty Short, a virologist and senior lecturer at
“Recent phase 2/3 data from both Novavax and Johnson & Johnson suggest reduced protection against the South African variant,” Dr. Short reports.
“The Oxford/AstraZeneca vaccine group also released data suggesting its vaccine offers only minimal protection against mild-moderate disease caused by this variant.”
“It’s important to recognize ‘reduced protection’ doesn’t mean
no protection at all, and that data are still emerging” and
“What’s more, numerous vaccine manufacturers are now investigating whether tweaks to the vaccines can improve their performance against the emerging variants,” added Dr. Short.
Dr. Kirsty Short, a virologist and senior lecturer at The University of Queensland